Aarhus Universitets segl

NEW REVOLUTIONARY ANTIFUNGAL DRUG - A Paradigm Shift In The Treatment Of Invasive Aspergillosis

Projekter: ProjektForskning

Se relationer på Aarhus Universitet


PulmoPharma’s Puldium™ is new inhalable combination drug for the treatment of invasive aspergillosis in the lungs.
This kind of combination treatments are known to have a very low or not existing risk of developing drug resistance.
Pre-clinical studies have already shown the efficacy of Puldium™ and its clear superiority over the existing used treatments.
We’re currently doing in vitro/in vivo studies and preparing for a toxicology study and Phase IIa studies.
PulmoPharma is actively looking for collaboration in the R&D phase and future commercial partner(s).
Effektiv start/slut dato01/08/202131/08/2024

ID: 258571741